Abstract
In a previous study we presented an assay for targeted mRNA sequencing for the identification of human body fluids, optimised for the Illumina MiSeq/FGx MPS platform. This assay, together with an additional in-house designed assay for the Ion Torrent PGM/S5 platform, formed the basis for a collaborative exercise within 17 EUROFORGEN and EDNAP laboratories, in order to test the efficacy of targeted mRNA sequencing to identify body fluids. The task was to analyse the supplied dried body fluid stains and, optionally, participants' own bona fide or mock casework samples of human origin, according to specified protocols. The provided primer pools for the Illumina MiSeq/FGx and the Ion Torrent PGM/S5 platforms included 33 and 29 body fluid specific target sequences, respectively, to identify blood, saliva, semen, vaginal secretion, menstrual blood and skin. The results demonstrated moderate to high count values in the body fluid or tissue of interest with little to no counts in non-target body fluids. There was some interlaboratory variability in read counts, but overall the results of the laboratories were comparable in that highly expressed markers showed high read counts and less expressed markers lower counts. We performed a partial least squares analysis (PLS) on the data, where blood, menstrual blood, saliva and semen markers and samples clustered well. The results of this collaborative mRNA massively parallel sequencing (MPS) exercise support targeted mRNA sequencing as a reliable body fluid identification method that could be added to the repertory of forensic MPS panels.
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Introuction
Messenger RNA (mRNA) profiling has emerged in the last years as a new method for body fluid identification [1] [2] [3] [4] [5] [6] . It is based on the premise that each single tissue type is comprised of cells that have a unique transcriptome or gene expression (i.e. mRNA) profile. A number of markers have been identified for the forensically most relevant body fluids and tissues: blood, saliva, semen, vaginal secretion, menstrual blood and skin [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . Conventional mRNA profiling includes the following steps: RNA extraction, reverse transcription, tissue-specific PCR amplification and separation/detection with capillary electrophoresis (CE). The main advantages of mRNA profiling compared to conventional protein-based methods are a significant improvement in specificity, additional body fluids and tissues that can be tested (e.g. menstrual blood, vaginal secretion, nasal secretion, skin), the ability of multiplexing numerous mRNA markers for the identification of one or several body fluids and the possibility of simultaneously isolating RNA and DNA from the same piece of stain [19, 20] . The co-extraction of RNA and DNA allows for positive identification of the tissue/fluid source of origin by mRNA profiling as well as a simultaneous identification of the body fluid / tissue donor by STR profiling [21] .
The European DNA Profiling Group (EDNAP -http://www.isfg.org/EDNAP) performed six collaborative exercises during the last few years, in order to evaluate the robustness and reproducibility of CE-based mRNA profiling for blood, saliva, semen, menstrual blood, vaginal secretion and skin identification [22] [23] [24] [25] [26] . The results of these collaborative exercises support mRNA profiling as a reliable body fluid identification method that can easily be combined with current STR typing technology.
The introduction of massively parallel sequencing (MPS) also revolutionised transcriptomics. With targeted mRNA sequencing approaches it is possible to multiplex numerous markers avoiding time and sample consumption from multiple separate analyses. In addition, mRNA sequencing provides a larger dynamic range for quantitative analyses and the possibility to identify sequence variation, compared to the endpoint PCR/CE-based methods. Furthermore, MPS is specifically suitable for degraded samples, since mRNA is usually fragmented prior to the reverse transcription step in MPS protocols. Within the EUROFORGEN Network of Excellence (https://www.euroforgen.eu) we established a targeted mRNA massively parallel sequencing approach for body fluid/tissue identification [27] . This included the evaluation of a suitable library preparation protocol and sequencing platform, as well as the selection of the most appropriate markers, based on the experience with the PCR/CE-system.
The assay was developed to analyse six different body fluids / tissues, i.e. blood,
semen, saliva, vaginal secretion, menstrual blood and skin. In a proof-of-conceptpaper the assay we developed and ran on the Illumina MiSeq/FGx platform was demonstrated to identify body fluids with good sensitivity in single source and mixed stains [27] .
Based on this knowledge, a EUROFORGEN / EDNAP collaborative mRNA MPS exercise was organised by the Zurich Institute of Forensic Medicine, Switzerland.
In addition to the Illumina MiSeq/FGx specific assay, we developed a separate assay for the Ion Torrent PGM/S5 platform (Ion AmpliSeq™ RNA custom panel, Thermo Fisher Scientific, Waltham, MA), enabling laboratories running this alternative MPS system to participate in the collaborative exercise. We started with a PGM/S5 panel including the same 33 biomarkers that were used for the MiSeq/FGx specific assay. Then, in an iterative process, we added new markers and removed poorly performing markers (panels 2 and 3 included 61 and 37 biomarkers, respectively). The final PGM/S5 assay included 29 biomarkers in total. In this exercise, either of the two multiplexes was provided to each participating laboratory. The exercise included the analysis of 16 and 8 mock casework samples for MiSeq/FGx and PGM/S5 users respectively, and optionally additional bona fide or mock casework samples from the participating laboratories. Here, we present data from the 17 participating laboratories.
Materials and methods

Samples and materials
The organising laboratory (Zurich Institute of Forensic Medicine) sent 8 stains to laboratories using PGM/S5 (n=9) and 16 stains to laboratories using MiSeq/FGx (n=10). Two laboratories performed the experiment on both platforms. Samples (Table S1 ). All swabs were dried at room temperature for at least 12 hours.
Laboratories using MiSeq/FGx were asked to analyse 8 additional stains containing either human blood, semen, saliva, vaginal secretion, menstrual blood or skin or any mixtures thereof, but not more than 2 body fluids/tissues per stain ( 
RNA-extraction and quantification
Laboratories could use any RNA extraction method of their choice. The organising laboratory recommended a manual organic method [1] and a silica column based method (RNeasy® Mini Kit, Qiagen, Venlo, NL). For laboratories using a PGM/S5, it was highly recommended to use the organic extraction method which results in higher RNA yields. We suggested using the TURBO DNA-free™ kit (Thermo Fisher Scientific) for DNase treatment.
To define the desired input amount of RNA, laboratories were advised to quantify the RNA extracts using fluorescence or electrophoresis based quantification methods. The following methods were recommended: 1) Quant-iT RiboGreen RNA kit / Fluorescence microplate reader (high-and low-range protocol options) (Thermo Fisher Scientific); 2) QuantiFluor RNA System / QuantiFluor-ST Fluorometer (Promega, Madison, WI); 3) Quant-iT RNA assay kit / Qubit Fluorometer (Thermo Fisher Scientific); 4) Bioanalyzer (normally bad RNA quality / low RIN numbers with these kind of samples). In case the laboratories had no means of quantifying the RNA extracts, the organising laboratory proposed a specific input volume for each stain (Table S3 ).
Library preparation and sequencing
The MiSeq/FGx library preparation was performed according to the manufacturer's protocol (#15034665 v01, January 2016) using 50 ng RNA in 3 µL and following the "degraded RNA" protocol. Targets were amplified using 34 cycles. The final library, diluted to 6 pM, was sequenced using 51 cycles singleread and the MiSeq Reagent Kit v3 (Illumina Inc.). The PGM/S5 library preparation was performed according to the manufacturer's protocol 
Data analysis
Following sequencing, the organising laboratory collected the sequencing raw data (fastq/bam files) for further analyses. MiSeq/FGx fastq files were used to run the TruSeq Targeted RNA application on BaseSpace cloud (Illumina Inc.), resulting in a matrix displaying read counts per amplicon in each sample. PGM/S5 bam files were used as input files for the Ion AmpliSeq™ RNA plugin on the Torrent Server (Torrent Suite Software v4.6, Thermo Fisher Scientific), resulting in an amplicon coverage file.
Statistical analyses
To visualise major trends in the data, we performed a partial least squares (PLS) analysis. PLS is a decomposition technique similar to principal component analysis (PCA). It searches for a small set of orthogonal components, or latent variables, that explain as much as possible of the covariance between a set of predictor variables and a dependent variable [29] . In this case the predictor variables correspond to the mRNA markers, and the dependent variable is the body fluid category of each sample. An advantage of using PLS compared to
evaluating each mRNA marker separately, is that PLS considers the coexpression of the markers. Information about mRNA markers that are not expressed may be just as valuable as information about markers that are expressed, if this is a repeated pattern for samples of that body fluid.
The PLS analysis requires a normalisation of the data to adjust for different input amounts. A centered log-ratio (CLR) transformation [28] , commonly used for read count data, divides each read count by the read counts sum for the sample, and takes the log-ratio of these relative reads. To avoid zero reads, one pseudo count was added to each read count.
R scripts presented here are available from the authors upon request.
Results
Samples, materials and methods
Seventeen laboratories participated in the exercise, 10 using the MiSeq/FGx platform and 9 using the PGM/S5 platform (2 laboratories did the experiments on both platforms). We provided the protocols and primer pools for PGM/S5 and MiSeq/FGx to assure conditions were as similar as possible for all laboratories.
To keep costs reasonable, the smallest possible modular number of samples was analysed, which comprised 24 samples for the MiSeq/FGx laboratories (half of a TruSeq Targeted RNA Expression Panel Kit) and 8 samples for the PGM/S5 laboratories (Ion AmpliSeq™ RNA Library Kit). The samples and primers were sent at ambient temperature by courier mail. Fifteen laboratories received the parcel within 4 days, only one parcel was held back by customs and was in transit for 16 days. Two laboratories did not store the primers immediately at -20°C and kept them at room temperature for 1-3 weeks. The laboratories were asked to fill
in a questionnaire on what methods they used, their quantification results, and other relevant information about the experiments conducted (Table S3 ). Table 2 shows the RNA extraction and quantification methods used by the participating laboratories. As predicted, the manual organic extraction method resulted in much higher RNA yields than the inorganic kit-based methods.
Data analysis
The final data analysis was performed by the organising laboratory. We identified issues with counting reads of some markers using the Ion AmpliSeq™ RNA plugin ( Figure S1 ). Usually, only end-to-end reads are considered for the total read count of each marker. Figure S1a shows how the amplicons/reads along the target sequence are expected to look like when the markers are analysed end-toend. Most of the markers were analysed in this manner. The target sequence of marker SEMG2 was only partly covered and the end-to-end reads did not represent the actual coverage ( Figure S1b ). For SEMG2, all reads were counted although shorter than the target region. For marker MUC7 a lot of short reads were aligned to a region adjacent to the actual target region and were wrongly counted as target reads ( Figure S1c ). To remove the non-target short reads, endto-end analysis of marker MUC7 was performed. The analysis of MiSeq/FGx data did not show any of these issues. were similar in that markers of the target body fluid were highly expressed, some markers showed higher reads with the MiSeq/FGx or PGM/S5 assay. This is most likely a result of different primer design, PCR efficiency and existing isoforms.
Non-specific reads were covered on average 1650x for MiSeq/FGx and 1945x for PGM/S5.
In Figure 2 the read counts of the laboratories are compared (MiSeq/FGx laboratories 1-7, PGM/S5 laboratories 6, 7, 10-16). Three MiSeq/FGx laboratories (laboratories 8, 9 and 17) had no or only a few specific reads and/or some nonspecific reads. Interestingly, these included the two laboratories not using the RT enzyme that was recommended in the library preparation protocol. Results from laboratories 8, 9 and 17 were therefore omitted from further analyses. All results of the PGM/S5 laboratories could be included in downstream analyses. There was some inter-laboratory variability in read counts, but overall the results of the laboratories were consistent, in that highly expressed markers showed high and less expressed markers lower read counts. For PGM/S5 the detection of the lowlevel RNA stains (blood and semen) worked only for the laboratories that used a manual organic extraction method, where the required RNA input of 50 ng was achieved.
As shown in Figures 1 and 2 , variability could also be observed among markers within a body fluid / tissue. Results from the MiSeq/FGx assay showed highest reads from ALAS2 and AMICA1 for blood samples, from PRM1 and PRM2 for semen samples and from HTN3 for saliva samples. Corresponding results from samples analysed with the PGM/S5 assay were difficult to interpret for the low-
level RNA stains blood and semen. For saliva samples, STATH and MUC7 were highly expressed. HTN3 was -in contrast to the MiSeq/FGx assay -the least expressed marker, probably due to unfavourable primer-or marker design.
FAM83D and MMP10 were the most prominent markers in both panels for vaginal secretion and menstrual blood, respectively. Skin markers were observed only sporadically and only with the MiSeq/FGx assay.
Body fluid inference
Raw read counts were used to calculate mean percent contributions of all six body fluid categories for the analysed stains (Table 3 ). Samples with < 5000 total reads were excluded. All blood, semen, vaginal secretion, menstrual blood and skin samples showed expected contributions and were correctly identified with both the MiSeq/FGx and the PGM/S5 assay. For saliva samples, moderate contributions from vaginal secretion markers could be observed and the identification was therefore inconclusive. All four mixed samples were correctly identified.
Statistical analyses
We performed a partial least squares (PLS) analysis on both the MiSeq/FGx and the PGM/S5 data to be able to visualise and compare any major trends in the two data sets. The plots in Figure 3 show the correlation between the markers and the Table S2 lists the additional stains which were analysed by the MiSeq/FGx laboratories. Figure 8 urine. All three samples are positioned randomly and not within specific groups, with even the two urine samples being far apart from each other in both score plots.
Discussion
In a previous study we presented an assay for targeted mRNA sequencing for the identification of human body fluids, optimised for the MiSeq/FGx MPS platform [27] . To encourage other laboratories not having access to a MiSeq/FGx platform to participate, an ad hoc in-house PGM/S5 assay was developed for this study.
The purpose of this study was to implement and evaluate the MPS application in an extended group. We organised a collaborative exercise within 17 EUROFORGEN and EDNAP laboratories to test the platform-specific assays. and real casework samples will be included to assess more systematically the performance of the application to cope with old, degraded and compromised samples.
Most of the laboratories had previous experience with mRNA analyses from former collaborative exercises [22] [23] [24] [25] [26] 30] and some prior knowledge of MiSeq/FGx / PGM/S5 library preparation procedures. The laboratories applied their preferred RNA extraction methods, but all further steps were performed according to our provided protocols. The library preparation protocols of the assays are straightforward, although the PGM/S5 workflow (except for protocols including the Ion Chef™ robot) is more time-consuming and requires more hands-on experience (e.g. chip loading) than the MiSeq/FGx workflow.
The manual organic RNA extraction that was recommended by the organising laboratory is a simple and cheap method providing higher RNA yields than silicacolumn based kit extractions (based on our own experience). This was confirmed as laboratories using the organic RNA extraction recovered considerably higher RNA concentrations and correspondingly higher read counts. However, if DNA has to be analysed in parallel from a casework sample, different extraction methods allowing RNA and DNA to be recovered from the same sample have to be applied.
The RNA quantification methods NanoDrop™ and Qubit™ are not very specific and sensitive. For Qubit™ the lower detection limit was reached especially for blood, semen and skin. NanoDrop™, which is based on a spectrophotometric measurement, rather overestimated the actual RNA quantities since residual DNA and other contaminants, also absorbing light at 280 nm, are quantified as well.
One laboratory using NanoDrop™ did take this into account and used the proposed input volumes for library preparation instead of relying on NanoDrop™ results. Quantus™ and Quant-iT™ Ribogreen were more sensitive compared to Qubit™ and were able to quantify even the low input samples.
Both RNA extraction and quantification are important steps for forensic RNA analyses, especially for sequencing applications where sufficient input amounts are pivotal for optimal assay performance. Nevertheless, for some body fluids (e.g. blood, semen and skin), despite the ideal and high input RNA stains and the use of a manual organic RNA extraction method, the desired input amount of 50 ng could not be reached. Therefore, extraction methods with maximal yields as well as specific and sensitive quantification methods are essential.
The results of three laboratories had to be excluded from final evaluation, because of no or non-specific reads. Two of the laboratories did not use the RT enzyme which is part of the library preparation protocol. For the reverse transcription reaction several brands of RT enzymes might work. However, some incompatibilities of buffers or other reagents from these RT reactions may have had a negative influence on subsequent steps of library preparation. For the third laboratory we could not find an explanation for the poor results. when the same RNA is analysed with the two different panels (Figure 1 ). There was some inter-laboratory variability in read counts, especially for skin and vaginal secretion samples, but overall the results of the laboratories were consistent, highly expressed markers showed higher and less expressed markers lower read counts. Due to the relatedness of some body fluids that are detected with the presented assays, some cross reaction reads for some markers were not surprising. For example, markers for vaginal secretion could sporadically be observed also in saliva samples since both body fluids are produced by mucous, epithelial cells. To visualise the complex data, we performed a PLS analysis, where blood, menstrual blood, saliva, semen and vaginal secretion markers and samples clustered nicely, although better for MiSeq/FGx than for PGM/S5 data.
This reflects the issues with low RNA inputs that could be observed for the PGM/S5 workflow, resulting in few or no specific reads. Skin samples in particular are difficult in several regards. Usually, RNA yields are very low for contact stains.
In addition, there was mainly one skin marker (LCE1C) that seemed to be sensitive enough to be detected in skin samples.
The score plots of the mixed samples showed that they do not cluster exactly in between the two involved body fluids but rather with one of them, depending on the type of mixture. This pattern could also be observed using average read counts, where one of the two body fluids was dominant, leading to a higher coverage than for the other body fluid / tissue. The dominant body fluid in mixtures (e.g. vaginal secretion in semen-vaginal secretion mixtures or menstrual blood in semen-menstrual blood mixtures) was usually the body fluid that also had higher RNA yields in single stains. It is therefore important that for mixtures containing body fluids with usually low RNA amounts, e.g. from blood, semen, The presented prototype assays and the corresponding results from the participating laboratories will serve as a basis for improvements regarding marker selection, library preparation and sequencing. Our results suggest that the analysis of mRNA by targeting body fluid / tissue specific amplicons is a promising tool for body fluid identification. Future developments of the current assay will employ coding region SNPs (cSNPs) within the tissue specific genes that vary considerably within individuals. In this way we will be able to assign a body fluid to a specific individual in mixed donor stains. This will be the task for a second collaborative exercise within the same laboratories. (EUROFORGEN-NoE). We thank Nair Gouveia f , Iva Gomes j , Arwin Ralf m and Mayra Eduardoff q for technical assistance and discussion. We thank Titia Sijen t for coordinating the study at the NFI and critically reading the manuscript. We are grateful to all volunteers who provided samples for this study. Table 1 ). 
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